NCT04661150 2026-04-16A Study of Atezolizumab and Trastuzumab in Combination With Capecitabine and Oxaliplatin in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal JunctionHoffmann-La RochePhase 2 Active not recruiting42 enrolled 9 charts
NCT02465060 2026-04-13Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)National Cancer Institute (NCI)Phase 2 Active not recruiting6,452 enrolled 2 FDA
NCT04430738 2026-02-24Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal CancersSeagen Inc.Phase 2 Active not recruiting40 enrolled 67 charts
NCT05980481 2025-09-29A Study of RC48-ADC Combination Therapies as First-line Treatment in Advanced Metastatic Gastric CancerRemeGen Co., Ltd.Phase 2/3 Active not recruiting201 enrolled
NCT05002127 2025-08-07A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)ALX Oncology Inc.Phase 2/3 Active not recruiting127 enrolled
NCT04908813 2024-04-15Study of HLX22 in Combanition With Trastuzumab and Chemotherapy Versus Placebo in Combination With Trastuzumab and Chemotherapy for Treatment of Locally Advanced or Metastatic Gastric CancerShanghai Henlius BiotechPhase 2 Active not recruiting150 enrolled
NCT03950271 2024-02-28SHR-1210 Combined With Trastuzumab , Oxaliplatin and Capecitabine for Neoadjuvant Therapy of Gastric Adenocarcinoma/Gastroesophageal Junction AdenocarcinomaHenan Cancer HospitalPhase 2 Active not recruiting25 enrolled